Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Chimera Antigen Receptor (CAR)”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT02650999
What this trial is testing

Pembrolizumab in Patients Failing to Respond to or Relapsing After CAR T Cell Therapy for Relapsed or Refractory Lymphomas

Who this might be right for
CD19+ Diffuse Large B-cell LymphomasFollicular LymphomasMantle Cell Lymphomas
Abramson Cancer Center at Penn Medicine 12
Early research (Phase 1)Looking for participantsNCT05388695
What this trial is testing

To Observe the Dual-target Chimeric Antigen Receptor T Cells in the Treatment of B Cell Hematologic Tumors

Who this might be right for
19 and 22+ B Cell Hematologic Tumors19 and 20+ B Cell Hematologic Tumors
Hebei Senlang Biotechnology Inc., Ltd. 100
Testing effectiveness (Phase 2)Active Not RecruitingNCT06617793
What this trial is testing

An Open-label Study to Assess the Safety, Efficacy, and Cellular Kinetics of YTB323 in Relapsing Multiple Sclerosis

Who this might be right for
Relapsing Multiple Sclerosis
Novartis Pharmaceuticals 28
Early research (Phase 1)Looking for participantsNCT07572136
What this trial is testing

Anti-CRLF2-R/TSLPR Chimeric Antigen Receptor T Cells (TSLPR-CART) in Participants With Recurrent or Refractory CRLF2-R/TSLPR-Overexpressing B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Who this might be right for
B-AllAcute Lymphoblastic Leukemia
National Cancer Institute (NCI) 57
Testing effectiveness (Phase 2)Looking for participantsNCT06838832
What this trial is testing

Novel Allogenic CD19-targeting CAR-γδT Cell Therapy (QH103E) in r/r NHL

Who this might be right for
Non-hodgkin Lymphoma,B Cell
Chinese PLA General Hospital 30
Large-scale testing (Phase 3)Not Yet RecruitingNCT07735637
What this trial is testing

A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6).

Who this might be right for
Newly Diagnosed Multiple Myeloma (NDMM)
AstraZeneca 750
Early research (Phase 1)Active Not RecruitingNCT03774654
What this trial is testing

CD19.CAR Allogeneic NKT for Patients With Relapsed or Refractory B-Cell Malignancies (ANCHOR)

Who this might be right for
Refractory B-Cell Non-Hodgkin LymphomaRefractory B-Cell Small Lymphocytic LymphomaRelapsed Adult ALL+2 more
Baylor College of Medicine 13
Testing effectiveness (Phase 2)Looking for participantsNCT05826535
What this trial is testing

Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma

Who this might be right for
Relapsed Non-Hodgkin LymphomaRefractory Non-Hodgkin LymphomaNon-Hodgkin Lymphoma+1 more
Lyell Immunopharma, Inc. 270
Testing effectiveness (Phase 2)Looking for participantsNCT06045910
What this trial is testing

A Phase I/II Trial of ALETA-001 for the Treatment of Participants With B-cell Malignancies

Who this might be right for
Lymphoma, Non-HodgkinLymphoma, Large B-Cell, DiffuseLymphoma, Mantle-Cell+3 more
Cancer Research UK 84
Testing effectiveness (Phase 2)Looking for participantsNCT06182696
What this trial is testing

OriCAR-017 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of R/RMM

Who this might be right for
Relapsed and/or Refractory Multiple Myeloma
OriCell Therapeutics Co., Ltd. 83
Testing effectiveness (Phase 2)Not Yet RecruitingNCT02992210
What this trial is testing

Study on GD2 Positive Solid Tumors by 4SCAR-GD2

Who this might be right for
Solid Tumor
Shenzhen Geno-Immune Medical Institute 10
Very early researchLooking for participantsNCT06337474
What this trial is testing

An Clinical Study of CD19 CAR NK Cells for the Treatment of Refractory Primary Immune Thrombocytopenia

Who this might be right for
Thrombocytopenia Alloimmune
Changzhou No.2 People's Hospital 9
Testing effectiveness (Phase 2)UnknownNCT03182803
What this trial is testing

CTLA-4 and PD-1 Antibodies Expressing Mesothelin-CAR-T Cells for Mesothelin Positive Advanced Solid Tumor

Who this might be right for
Advanced Solid Tumor
Shanghai Cell Therapy Research Institute 40
Early research (Phase 1)Looking for participantsNCT06909474
What this trial is testing

Clinical Trial of CD5-targeted CAR-NK Therapy for Relapse/Refractory T-Cell Hematologic Malignancies

Who this might be right for
T-ALL/Lymphoma
Chongqing Precision Biotech Co., Ltd 15
Large-scale testing (Phase 3)Looking for participantsNCT06615479
What this trial is testing

Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)

Who this might be right for
Relapsed or Refractory Multiple Myeloma (RRMM)
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company 440
Early research (Phase 1)UnknownNCT03545815
What this trial is testing

Study of CRISPR-Cas9 Mediated PD-1 and TCR Gene-knocked Out Mesothelin-directed CAR-T Cells in Patients With Mesothelin Positive Multiple Solid Tumors.

Who this might be right for
Solid Tumor, Adult
Chinese PLA General Hospital 10
Early research (Phase 1)UnknownNCT03563326
What this trial is testing

Intraperitoneal Infusion of EpCAM CAR-T Cell in Advanced Gastric Cancer With Peritoneal Metastasis (WCH-GC-CART)

Who this might be right for
Neoplasm, StomachMetastases, NeoplasmNeoplasm Seeding
Jian-Kun Hu 40
Early research (Phase 1)UnknownNCT04153799
What this trial is testing

Study of CXCR5 Modified EGFE Chimeric Antigen Receptor Autologous T Cells in EGFR- Positive Patients With Advanced Non-small Cell Lung Cancer

Who this might be right for
Non Small Cell Lung Cancer
Sun Yat-sen University 11
Early research (Phase 1)Study completedNCT02761915
What this trial is testing

A Phase I Trial of Anti-GD2 T-cells (1RG-CART)

Who this might be right for
Relapsed or Refractory Neuroblastoma
Cancer Research UK 17
Testing effectiveness (Phase 2)Ended earlyNCT05489991
What this trial is testing

TmPSMA-02 Chimeric Antigen Receptor (CAR) T-cells in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)

Who this might be right for
Metastatic Castration-resistant Prostate Cancer
Tceleron Therapeutics, Inc. 1
Next Page